Trial intelligence / Profile preview

Phase II study of dacomitinib in EGFR-mutant NSCLC with non-irradiated brain metastases

KCT0005748Phase 2Completed

Sponsor

Pfizer

Start

Jan 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1